Fig. 3From: Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyOverall survival of matched ZUMA-3 and SCHOLAR-3 treated patients. Kaplan–Meier OS estimates of ZUMA-3 and SCA patients who were previously naïve to blinatumomab and inotuzumab (SCA-1; A), patients who were previously treated with blinatumomab or inotuzumab (SCA-2, B) and all matched patients (SCA-combined; C). CR = complete remission. CRi = complete remission with incomplete hematological recovery. NE = not estimableBack to article page